The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Category Archives: Jeremy Grushcow

Biotech Trends Update — IP Constituencies: Innovator-Generic Mixing Continues in Canada

As traditional pharma companies continue to diversify their revenue sources in the face of their pending patent cliffs, we have followed their entry into and expansion of their generics business lines. We have also noted activity in the reverse – generics companies developing novel products to build their margins and take advantage of their production capacity and [...]

BIO World Congress on Industrial Biotechnology & Bioprocessing — Day 1 Review

We attended several sessions yesterday and learned about biofuels and bioproducts investment; bioingredients for food and nutrition; and strategies for profitable commercialization of renewable chemicals, among others. One of the highlights was the lunch plenary, where panelists Brian J.M. Ames (DOW Chemical),  Balu Sarma (Praj Matrix), Feike Sijbesma (DSM) and Peter Williams (INEOS Technologies) addressed a panel discussion entitled [...]

BIO World Congress on Industrial Biotechnology & Bioprocessing

This year’s World Congress on Industrial Biotechnology starts today in Toronto. A report from The Milken Institute released into the lead-up before the conference includes some interesting data: Industrial biotechnology received $1.48 billion in venture investment from 2004 to 2009, compared to $1.99 billion for biofuels and $17.48 billion for therapeutic biotech plays. Up to 78% of [...]

Myriad Genetics v ACLU in the Federal Circuit

The ACLU had its day in court at the Federal Circuit yesterday, with oral arguments occupying 70 minutes of the court’s time in front of an audience of “hundreds” according to coverage from The Salt Lake Tribune (Myriad’s hometown paper). This case, you will recall, is a challenge to the patentability of isolated DNA. When [...]

Stability at the Top: A Look at Top Biotech VC Deals from 2007-2010

FierceBiotech published the top 15 biotech VC deals of 2010 last week, measured by dollars invested. Since they noted an overall uptick in investments in 2010, it seemed like a worthwhile time to look back. Here’s what U.S. VC investment in biopharma and medical devices looked like from 2007 to 2010 (normalized to 2007 levels): Not [...]

Biotech Trends in 2011: Biosimilars

In our original post on biosimilars, Lumira Capital’s Beni Rovinski set out the business opportunities, the technical challenges and the regulatory hurdles facing follow-on biologics in 2009. Since then, as Beni predicted, a series of pharma deals have followed Merck’s Insimed acquisition, and the regulatory framework in North America has been clarified substantially, with final Health Canada guidance having been [...]

Weekend Reading: This Week in the Twitterverse

Catch up on the week’s biotech developments and news from our Twitter stream @crossborderbio: Congrats to Chris Arsenault, Announced as Co-Chair of the Canadian Innovation Exchange http://eqent.me/gkggtr RT @CVCACanada Evolution, Vaccination, and Prostate health examination, in this week’s Friday Science Review: http://ow.ly/1aRBr1  Endo chief looks to spend $500M on diagnostics acquisitions http://bit.ly/h0hRe3 RT @FierceBiotech UCSF now has [...]

Biotech Trends in 2011: Transgenics

As our ability to manipulate the genomes of plants and animals grows, we can increase crop yields, reduce environmental impact, improve nutrition and turn barren land arable.  Canada, in particular, has been at the forefront of much of this technology: The Enviropig, developed in Guelph, Ontario, in 1999, produces phytase, an enzyme regular pigs lack, [...]

Biotech Trends in 2011: Commercialization by Non-Profit Foundations

Financing for biotech companies is a major part of my work at my real job, and the horrible financing environment in the wake of 2008′s financial crisis was one of the motivators for starting this blog. So, when nonprofit foundations started financing commercialization and product development in addition to their traditional role in financing research, it [...]

Weekend Reading: This Week in the Twitterverse

Catch up on the week’s biotech developments and news from our Twitter stream @crossborderbio: Top 5 Cross-Border Biotech Blog topics of 2010 http://bit.ly/gocDJb via @slaw_dot_ca  The House is going to repeal Obamacare; other than that bicameral thing, that seems straightforward: http://goo.gl/0DiN RT @randypicker Stem cells that divide in two, Tobacco vaccine to stop the flu: This week’s [...]

Biotech Trends in 2011: Comparative Effectiveness and Personalized Medicine

When this blog was launched in 2009, comparative effectiveness and personalized medicine were fairly new features in the North American landscape. Our initial argument that they were related topics — determining which treatment is best depends on which patient is being treated – was soon bolstered by the comparative effectiveness provisions in the U.S. stimulus bill and new personalized [...]

Biotech Trends in 2011: Social Media in Biotech and Healthcare

Use of social media by pharmaceutical companies, biotechs, and industry observers will continue to grow in scale, value and importance this year. The emergence of Twitter as a public health surveillance tool and the pending (still pending…) release of the FDA’s social media guidelines will contribute to this growth in the short term, and we’ll continue to [...]

Weekend Reading: This Week in the Twitterverse

Social media, publication quality, Canadian VC policy and exhaustion (mine and patents’) make for a light dose of interesting reading this weekend: Friday Science Review: stagnant technologies in Africa, congenital blindness in children and chronic pain in the crosshairs… http://ow.ly/1auHag Social Media Reshaping Healthcare: Some cool data on the use of Twitter as a Public Health [...]

This Week in the Twitterverse – Weekend Reading

Here’s your dose of weekly biotech news, all wrapped up in one weekend-friendly package: VenGrowth Funds Receive Non-Binding Merger Proposal from GrowthWorks Canadian Fund http://eqent.me/hyhgU Oncolytic viruses for cancer therapy and synthetic promoters for diabetes therapy in this week’s Friday Science Review!http://bit.ly/g16v6Q Cephalon strikes record $2B stem cell pact with Mesoblast. $130m upfront+$220m for 20%, $1.7b later… http://bit.ly/dRGQlI [...]

Biotech Trends Update — IP Constituencies: Indian Industry Lobbies to Keep IP Out of Free Trade Agreement with EU

An article in yesterday’s Hindu Business Line says the Indian Drug Manufacturers’ Association is lobbying heavily to keep data protection and other innovator-friendly IP provisions out of the free trade agreement being negotiated between India and the EU. But, with Glenmark and Jubilant on the rise, and with even Biocon carrying the R&D water in its [...]

This Week in the Twitterverse: Weekend Reading

Here’s your dose of weekly biotech news, all wrapped up in one weekend-friendly package thanks to our Twitter stream: RT @ArsenicMicrobes: We come in peace – Funny! But agree with @matthewherper on this one: not an alien http://bit.ly/ebEPxe Never too early for biotechs and VCs to understand and plan for payer-focused endpoints http://bit.ly/fDEsbL via @InVivoBlogChris My short presentation [...]

Canadian Biotech and Healthcare Licensing Trends in 2010

I was fortunate this week to host the Canadian Healthcare Licensing Association‘s (CHLA’s) annual holiday get-together on behalf of Ogilvy Renault at our Toronto office (we hosted a parallel CHLA event in Montreal earlier this week). I presented a short slide deck on licensing trends in 2010, with data drawn from our Monday Biotech Deal [...]

This Week in the Twitterverse

Here’s your dose of weekly biotech news, all wrapped up in one weekend-friendly package thanks to our Twitter stream @crossborderbio: RT @CVCACanada: A Brave New World – Amid industry turmoil a rash of new VC players emerge in Canada – via @Techvibes http://bit.ly/dKErHk RT @mikesgene: Canada’s transgenic Enviropig is stuck in a genetic modification poke http://bit.ly/g2M6aQ [...]

This Week in the Twitterverse

Here’s your dose of weekly biotech news, all wrapped up in one weekend-friendly package thanks to our Twitter stream @crossborderbio: RT @CVCACanada: BDC’s Young Entrepreneur Awards Applications are now open!http://eqent.me/dlH2Rx RT @dgmacarthur: RT @genomicslawyer GLR Post: Recap from the Partners Personalized Medicine Conferencehttp://bit.ly/bGm6Nv RT @Michael_Gilman..just getting started on the West Coast,have a look at today’s [...]

Biotech in the Provinces: OBEST Launches Regional Meetings in Ontario; Western Canada Innovation Agreement to Provide Seed Funding

The Ontario Bioscience Economic Strategy Team (OBEST)* is holding regional cluster meetings starting today that will be chaired by bioscience CEOs from across the province. OBEST launched its evergreen strategy to sustain and grow the province’s health-science industry last week with a meeting of the OBEST advisory committee, which is chaired by Dr. Daniel Billen from [...]

New Firm, New Contributors Contribute to New Look

This morning Ogilvy Renault (my law firm) announced a planned merger with UK-based Norton Rose that will give us fantastic international capabilities, including a new global life sciences focus highlighting our Canadian strength. In addition to being a ground-breaking move for a Canadian firm, it is also exciting for the blog, where reporting has always [...]

This Week in the Twitterverse

Here’s your dose of weekly biotech news, all wrapped up in one weekend-friendly package thanks to our Twitter stream @crossborderbio: RT @mikesgene: Ontario Genomics Institute Invests in Personalized Medicine for Age-related Macular Degeneration http://bit.ly/dl9VwC w/video 23 hours ago GrowthWorks solicits votes against VenGrowth-Covington deal, wants time to make its own offer. http://eqent.me/cWw2aK via @CVCACanada TSX’s Raymond King [...]

This Week in the Twitterverse

Some weekend reading from our Twitter stream @crossborderbio: RT @mikesgene: Personal genomics tests prompt lifestyle changes http://bit.ly/9QsQFx #genome RT @dgmacarthur: Y Bombard: newborn blood spots are stored for up to 18 years in US, up to 30 years in Canada #ashg2010 U.S. Therapeutic Discovery Stimulus Reaches Biotechs in Canada, Israel, Germany http://ow.ly/19NEBF RT @patentlyo: Constitutional Inventors, [...]

U.S. Therapeutic Discovery Stimulus Reaches Biotechs in Canada, Israel, Germany

As part of the health reform bill, the U.S. launched a $1 billion Therapeutic Discovery Project tax credit/grant stimulus program. The program announced grant recipients this week, deploying $1 billion just over 7 months after the law was passed, and 5 months after the IRS guidelines were released implementing the project. A full list of [...]

This Week in the Twitterverse

If you’re not following our Twitter stream @crossborderbio, here’s what you missed this week: RT @JillLOsborne: An interesting look at tech tranfer in Canada http://bit.ly/9Zqbb7Thx Jill – it’s by Mark Curtis, new @crossborderbio ! How Canada can use science as a diplomatic tool to restore our int’l reputation.http://bit.ly/aavqsP by Mehrdad Hariri of @sciencepolicy Acadia gets rights [...]

Ten Business Law Tips for Startups

There are lots of collections of tips for startups that have excellent business advice on building your team, hitting product milestones and pitching to VCs; but not that many that give a corporate lawyer’s perspective. So here’s mine:* You May be a Genius, but You Are Not a Lawyer Your idea is brilliant and you [...]

Two MaRS Innovation Transactions Take Off

MaRS Innovation, the “integrated commercialization platform” responsible for commercializing inventions from 16 Toronto academic institutions, announced two deals last week. One spin-out and one out-license (pdf links). The spin-out: MI put $500,000 into Prof. Shana Kelley‘s new company, Xagenic, alongside a $300,000 loan from HTX; $200,000 from the Ontario Institute for Cancer Research; and $40,000 from [...]

This Week in the Twitterverse

Some weekend reading from our Twitter stream on @crossborderbio: Internal promoters: Pierre Meulien moves from GenomeBC to Genome Canada CEO http://bit.ly/czrWSc Glad to be following @sheffi ‘s tweets today from CER/PM summit at NIH http://bit.ly/b9vfiw I’ve seen that combo b4… http://bit.ly/9h4BJM Great call with @jordan_law21 @privacylawyer @scottwolfejr – prep for panel Connecting Social Media to Business [...]

Biotech Trends Update — Biosimilars Blur IP Constituencies: Novartis and Pfizer-Biocon are Featured in the Economist

Two 9-figure announcements this week mark a turning point for the biosimilars market, and one highlights the increasingly important role India plays in innovation. Pfizer linked up with India’s Biocon in a deal that will see Biocon take the lead in development of four biosimilar insulin products that gives Biocon $200 million up front. Coverage of [...]

Follow

Get every new post delivered to your Inbox.

Join 84 other followers